EWTX
EdgewiseยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
EWTX Profile
Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company which develops small molecule therapies for rare muscle diseases
1715 38th St., Boulder, CO 80301
--
Edgewise Therapeutics, Inc., a Delaware corporation incorporated in May 2017, is headquartered in Boulder, Colorado. The company is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing new therapies for serious, rare muscle diseases with unmet medical needs. The Company's lead product candidate, EDG-5506, is an oral small molecule drug designed to address the underlying causes of malnutrition, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). A pipeline of precision drug candidates for major muscle proteins and regulators to address a broad range of genetically defined muscle diseases.
